

Francesco Cottone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/593801/publications.pdf>

Version: 2024-02-01

67
papers

1,579
citations

430874

18
h-index

330143

37
g-index

68
all docs

68
docs citations

68
times ranked

2078
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e344-e351.	1.6	1
2	Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 471-474.	6.3	15
3	Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy. <i>Annals of Hematology</i> , 2022, 101, 749-754.	1.8	3
4	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 442-459.	0.4	7
5	Physicians's Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040.	2.8	5
6	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	1.3	10
7	Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis. <i>Value in Health</i> , 2021, 24, 250-267.	0.3	63
8	Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review. <i>Value in Health</i> , 2021, 24, 585-591.	0.3	42
9	The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study. <i>JMIR Research Protocols</i> , 2021, 10, e25271.	1.0	4
10	Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019. <i>Value in Health</i> , 2021, 24, 1715-1719.	0.3	6
11	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44.	5.0	11
12	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	5.2	5
13	Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry. <i>BMJ Supportive and Palliative Care</i> , 2020, 10, e35-e35.	1.6	14
14	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	7.2	35
15	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. <i>Quality of Life Research</i> , 2020, 29, 815-823.	3.1	12
16	Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review. <i>Quality of Life Research</i> , 2020, 29, 867-878.	3.1	19
17	Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. <i>Lancet Haematology</i> , 2020, 7, e892-e901.	4.6	23
18	Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 9-18.	5.0	10

#	ARTICLE	IF	CITATIONS
19	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	1.6	2
20	Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. <i>British Journal of Haematology</i> , 2020, 190, e304-e307.	2.5	1
21	EORTC QLU-C10D value sets for Austria, Italy, and Poland. <i>Quality of Life Research</i> , 2020, 29, 2485-2495.	3.1	21
22	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	7.2	14
23	Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making. <i>Cancer Medicine</i> , 2020, 9, 4039-4058.	2.8	11
24	Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials. <i>Value in Health</i> , 2020, 23, 666-673.	0.3	13
25	Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002281.	1.6	1
26	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. <i>Value in Health</i> , 2019, 22, 1303-1310.	0.3	18
27	Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. <i>BMC Urology</i> , 2019, 19, 86.	1.4	10
28	Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology. <i>Quality of Life Research</i> , 2019, 28, 1315-1325.	3.1	4
29	Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 279-288.	1.4	4
30	Propensity score methods and regression adjustment for analysis of nonrandomized studies with health-related quality of life outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 690-699.	1.9	13
31	Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review. <i>BMJ Supportive and Palliative Care</i> , 2019, 9, bmjspcare-2019-001902.	1.6	4
32	Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1598-1607.	7.2	15
33	Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 1-3.	2.2	9
34	Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. <i>Cancer</i> , 2018, 124, 2228-2237.	4.1	22
35	Patient-reported outcome assessment in acute leukemias: Moving beyond the barriers. <i>Cancer</i> , 2018, 124, 3066-3067.	4.1	1
36	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259.	4.1	31

#	ARTICLE	IF	CITATIONS
37	Evaluating methodological quality of Prognostic models Including Patient-reported Health outcomes in oncology (EPIPHANY): a systematic review protocol. <i>BMJ Open</i> , 2018, 8, e025054.	1.9	6
38	Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 228.	2.4	64
39	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 127.	2.4	6
40	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. <i>Blood</i> , 2018, 132, 2293-2293.	1.4	1
41	Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 204.	2.4	0
42	Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. <i>BMJ Supportive and Palliative Care</i> , 2016, 6, 80-88.	1.6	16
43	Pushing the boundaries of care in myelodysplastic syndromes: Physical exercise to improve fatigue and health-related quality of life outcomes. <i>Leukemia Research</i> , 2016, 49, 36-37.	0.8	1
44	Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. <i>Supportive Care in Cancer</i> , 2016, 24, 4887-4894.	2.2	18
45	Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. <i>American Journal of Hematology</i> , 2016, 91, 995-1001.	4.1	53
46	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 211-219.	1.8	18
47	Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2523-2524.	1.4	12
48	Reply to M. Koehler et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1091-1092.	1.6	0
49	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	10.7	76
50	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 859-865.	0.8	17
51	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	2.5	59
52	Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. <i>Haematologica</i> , 2014, 99, 788-793.	3.5	85
53	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. <i>Annals of Oncology</i> , 2014, 25, 447-454.	1.2	38
54	Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2014, 38, 294-298.	0.8	32

#	ARTICLE	IF	CITATIONS
55	Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 3406-3412.	1.6	76
56	Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review. <i>Leukemia Research</i> , 2013, 37, 206-213.	0.8	37
57	The added value of propensity score matching when using health-related quality of life reference data. <i>Statistics in Medicine</i> , 2013, 32, 5119-5132.	1.6	5
58	Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. <i>Leukemia</i> , 2013, 27, 1511-1519.	7.2	119
59	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013, 122, 770-770.	1.4	2
60	Health-Related Quality Of Life In Transfusion-Dependent Patients With Myelodysplastic Syndromes Treated With Deferasirox. A Multicenter Prospective Study. <i>Blood</i> , 2013, 122, 2980-2980.	1.4	0
61	Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. <i>British Journal of Cancer</i> , 2012, 107, 904-909.	6.4	100
62	Tyrosine-Kinase Inhibitors, Quality of Life and Symptom Burden in Chronic Myeloid Leukemia: What Have We Learned So Far?. <i>Blood</i> , 2012, 120, 4236-4236.	1.4	0
63	Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. <i>Blood</i> , 2012, 120, 3163-3163.	1.4	0
64	Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. <i>Blood</i> , 2012, 120, 4234-4234.	1.4	0
65	Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood</i> , 2011, 118, 4554-4560.	1.4	221
66	Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 2078-2078.	1.4	0
67	Leaving home, family support and intergenerational ties in Italy: Some regional differences. <i>Demographic Research</i> , 0, 21, 1-22.	3.0	38